Sentence examples for for treated with from inspiring English sources

Metabolic profiles obtained by 1H NMR spectra were able to differentiate the two cultivars for treated with respect to untreated samples.

Exposure of only 20 min increased the inhibition of E. coli by 18%% (ZnO-rod) and 13%% (ZnO-plate), whereas, for S. aureus, 22 % increase for treated with ZnO-rod and 21 % with ZnO-plate, compared with the unexposed.

No differences were observed in either TER (2614±187.1 and 2625±326.5 ohms-cm2 for treated with sham and 2CLP media respectively, mean ± SE).

Monocytes isolated from healthy donors were labelled with 5- and-6 -carboxyfluorescein diacetate, succinimidyl ester (5- and-6 -carboxyfluorescein0 min, washed and either kept untreated for treated with blocking antibodies against CXCR4 or CXCR7 or respective IgG controls for a further 30 min.

Moreover, pre-treatment with CQ resulted in increment of the percentage of GBC cells at the G0/ G1 phase, compared with the cells treated with 5-FU alone (52.7% compared to 74.6% for 5-FU alone and CQ + 5-FU in SGC-996 cells, 61.6% compared to 76.8% for treated with 5-FU alone and CQ + 5-FU in GBC-SD cells, respectively).

CQ pre-treatment resulted increasing of the percentage of apoptotic cells followed by 5-FU treatment (34.3% compared to 46.2% for treated with 5-FU alone and CQ + 5-FU in GBC-SD cells, 23.4% compared to 48.6% for 5-FU alone and CQ + 5-FU in SGC-996 cells, respectively).

Thus, executions for treating with complex hyperbolic PDEs, like the Navier Stokes PDE, can be found proficiently.

Furthermore, discharge capacity larger than 140 mAh g−1 can be obtained for treating with 200 W microwave energy for 30 min.

Present day survival for infants treated with ECMO for many diagnostic categories ranges between 90% to 100%.

For patients treated with hemiarthroplasty for displaced fractures, the response rate was 15% (778/5,317).

The mean values for ΔmTSS from baseline to week 24 were 1.0 for patients treated with placebo versus -0.2 for those treated with adalimumab (P < 0.001) [ 13].